Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 1
1981 1
1982 2
1983 1
1984 1
1986 1
1987 2
1988 3
1989 3
1991 1
1992 2
1993 1
1997 2
1998 1
1999 1
2000 1
2001 1
2002 1
2003 4
2004 5
2005 4
2006 4
2007 6
2008 7
2009 9
2010 12
2011 6
2012 6
2013 6
2014 4
2015 9
2016 4
2017 5
2018 3
2019 5
2020 5
2021 2
2022 4
2023 10
2024 6
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: chander p. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N. Filippi AR, et al. Among authors: chander p. ESMO Open. 2024 Jun;9(6):103464. doi: 10.1016/j.esmoop.2024.103464. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833971 Free PMC article.
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
Bradley JD, Sugawara S, Lee KH, Ostoros G, Demirkazik A, Zemanova M, Sriuranpong V, Gelatti ACZ, de Menezes JJ, Zurawski B, Newton M, Chander P, Jia N, Bielecka ZF, Özgüroğlu M; PACIFIC-2 Investigators. Bradley JD, et al. Among authors: chander p. J Clin Oncol. 2025 Nov 20;43(33):3610-3621. doi: 10.1200/JCO-25-00036. Epub 2025 Oct 13. J Clin Oncol. 2025. PMID: 41082707 Free PMC article. Clinical Trial.
The synaptic ectokinase VLK triggers the EphB2-NMDAR interaction to drive injury-induced pain.
Srikanth KD, Elahi H, Chander P, Washburn HR, Hassler S, Mwirigi JM, Kume M, Loucks J, Arjarapu R, Hodge R, He L, Mazhar K, Shiers SI, Sankaranarayanan I, Erdjument-Bromage H, Neubert TA, Dougherty PM, Campbell ZT, Paik R, Price TJ, Dalva MB. Srikanth KD, et al. Among authors: chander p. Science. 2025 Nov 20;390(6775):eadp1007. doi: 10.1126/science.adp1007. Epub 2025 Nov 20. Science. 2025. PMID: 41264708
Autotherapies: Enhancing Endogenous Healing and Regeneration.
Lumelsky N, O'Hayre M, Chander P, Shum L, Somerman MJ. Lumelsky N, et al. Among authors: chander p. Trends Mol Med. 2018 Nov;24(11):919-930. doi: 10.1016/j.molmed.2018.08.004. Epub 2018 Sep 10. Trends Mol Med. 2018. PMID: 30213702 Review.
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.
Garassino MC, Khalifa J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis DL, Migliorino MR, Delmonte A, Garcia Sánchez J, Chara Velarde LE, Bernabe R, Paz-Ares L, Chander P, Diaz Perez I, Foroutanpour K, Emeribe U, Faivre-Finn C. Garassino MC, et al. Among authors: chander p. ESMO Open. 2025 Jun;10(6):105071. doi: 10.1016/j.esmoop.2025.105071. Epub 2025 May 27. ESMO Open. 2025. PMID: 40435873 Free PMC article. Clinical Trial.
HIV-associated nephropathy: role of AT2R.
Salhan D, Sagar A, Kumar D, Rattanavich R, Rai P, Maheshwari S, Adabala M, Husain M, Ding G, Malhotra A, Chander PN, Singhal PC. Salhan D, et al. Among authors: chander pn. Cell Signal. 2012 Mar;24(3):734-41. doi: 10.1016/j.cellsig.2011.11.007. Epub 2011 Nov 13. Cell Signal. 2012. PMID: 22108089 Free PMC article.
145 results